Lung Cancer Trial, Not Yet Recruiting NCT07589101 Sponsor: Peking University Cancer Hospital & Institute Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Not Yet Recruiting

NCT07589101
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with a solid tumour (a type of cancer that forms a solid mass).
  • People who have areas of disease that can be measured and seen on medical imaging scans.
  • People whose doctors expect them to live for at least 12 weeks.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have serious problems with how their liver or kidneys are working.
  • Women who are planning to become pregnant, are currently pregnant, or are breastfeeding.
  • People who are unable to lie flat on their back for 30 minutes.
  • People who do not wish to take part in this clinical study.
  • People who have been diagnosed with claustrophobia (fear of enclosed spaces) or certain other mental health conditions.
  • People who have other health or personal circumstances that the trial doctor considers make participation unsuitable (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hua Zhu, Peking University Cancer Hospital & Institute

Phone: 010-88196495

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Peking University Cancer Hospital & Institute
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
30 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Radiation Dosimetry of 68Ga-MY; Standardized Uptake Value (SUV); The ratio of Tumor SUV to background SUV (SUVR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov